The current stock price of CGC is 1.66 USD. In the past month the price increased by 55.14%. In the past year, price decreased by -41.34%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.3 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 20.63 | 516.00B | ||
| MRK | MERCK & CO. INC. | 11.38 | 248.85B | ||
| PFE | PFIZER INC | 8.26 | 150.27B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.28 | 110.52B | ||
| ZTS | ZOETIS INC | 19.08 | 53.31B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.37 | 22.24B | ||
| VTRS | VIATRIS INC | 5 | 13.43B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.6 | 10.78B | ||
| CORT | CORCEPT THERAPEUTICS INC | 99.2 | 9.18B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.37B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.97B |
Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The company is headquartered in Smiths Falls, Ontario and currently employs 960 full-time employees. The company went IPO on 2010-06-04. The company delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.
CANOPY GROWTH CORP
1 Hershey Dr
Smiths Falls ONTARIO K7A0A8 CA
CEO: David Klein
Employees: 1029
Phone: 18555589333
Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The company is headquartered in Smiths Falls, Ontario and currently employs 960 full-time employees. The company went IPO on 2010-06-04. The company delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.
The current stock price of CGC is 1.66 USD. The price decreased by -4.6% in the last trading session.
CGC does not pay a dividend.
CGC has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
CGC stock is listed on the Nasdaq exchange.
CANOPY GROWTH CORP (CGC) has a market capitalization of 611.64M USD. This makes CGC a Small Cap stock.
The outstanding short interest for CANOPY GROWTH CORP (CGC) is 12.75% of its float.
ChartMill assigns a technical rating of 4 / 10 to CGC. When comparing the yearly performance of all stocks, CGC is a bad performer in the overall market: 78.17% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to CGC. While CGC seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CGC reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS increased by 58.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.07% | ||
| ROE | -52.42% | ||
| Debt/Equity | 0.33 |
13 analysts have analysed CGC and the average price target is 2.72 USD. This implies a price increase of 63.75% is expected in the next year compared to the current price of 1.66.
For the next year, analysts expect an EPS growth of 94.86% and a revenue growth 2.14% for CGC